Article
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
Journal of gastroenterology - 1 Jul 2011
Oze Tsugiko, Hiramatsu Naoki, Yakushijin Takayuki, Mochizuki Kiyoshi, Imanaka Kazuho, Yamada Akira, Oshita Masahide, Kaneko Akira, Hagiwara Hideki, Mita Eiji, Ito Toshifumi, Nagase Toshihiko, Inui Yoshiaki, Hijioka Taizo, Tamura Shinji, Yoshihara Harumasa, Hayashi Eijiro, Imai Yasuharu, Kato Michio, Hosui Atsushi, Miyagi Takuya, Yoshida Yuichi, Ishida Hisashi, Tatsumi Tomohide, Kiso Shinichi, Kanto Tatsuya, Kasahara Akinori, Takehara Tetsuo, Hayashi Norio
Abstract excerpt
BACKGROUND: Which patients with hepatitis C virus (HCV) genotype 1 can benefit from extended treatment with pegylated interferon (Peg-IFN) plus ribavirin is unknown, although the overall sustained virologic response (SVR) rate has been shown to improve in patients with a late virologic response (LVR), defined as detectable serum HCV RNA at week 12 and undetectable at week 24. METHODS: Among 1163 chronic hepatitis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
